Company intelligence / Profile preview

MagVenture

Farum, Capital Region, Denmark

Ownership: Private
Employees: ~245
Development stage: Other

Overview

MagVenture's TMS systems (notably MagPro) are FDA-cleared for the treatment of major depressive disorder (including with ultra-fast theta burst protocols) and as adjunct therapy for OCD in adults who failed prior antidepressant medication. Their systems are CE approved for further indications in Europe including addiction and comorbid anxiety in depression. The company’s products are widely adopted globally for both clinical and research use, and are featured in strategic collaborations (e.g., Magnus Medical’s SAINT therapy for depression).

Therapeutic areas: NeurologyPsychiatry
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Magnus Medical (collaboration for SAINT neuromodulation system)

Beyond the preview

Go deeper on MagVenture.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MagVenture.

Explore the full profile